C5a / Complement Component C5a Antibody (Antigen Affinity Purified)

Complement Component C5a / C5a Antibody ( Antigen Affinity Purified )

Complement Component C5a / C5a Antibody Product Information

• Immunogen: Recombinant human C5a protein ( Catalog#10604-HNAE )
• Antibody Type: Rabbit Polyclonal Antibody ( Antibody Purification Platform )
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: Produced in rabbits immunized with purified, human cell-derived, recombinant human C5a ( rh C5a ; Catalog#10604-HNAE ; Leu 679 - Arg 751 ). C5a specific IgG was purified by human C5a affinity chromatography

Complement Component C5a / C5a Antibody Usage Guide

• Specificity: Human Complement Component C5a / C5a
• Western blot: This antibody can be used at 0.1 - 0.2 μg/mL with the appropriate secondary reagents to detect human C5a in WB. Using a DAB detection system, the detection limit for human C5a is approximately 0.5 ng/lane under non-reducing conditions and 1 ng/lane under reducing conditions
• Direct ELISA: This antibody can be used at 0.1 - 0.2 μg/mL with the appropriate secondary reagents to detect human C5a. The detection limit for human C5a is approximately 0.00975 ng/well
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Complement Component C5a / C5a Antibody Background

C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 α-chain during the classical, alternative, and lectin pathways of complement activation. The structure of C5a includes a core region consisting of four, anti-parallel alpha-helices held together by three disulfide linkages and a structured C-terminal tail, and C5a is rapidly metabolised by carboxypeptidase B to a 73 amino acid low activity form, C5a des-Arg. C5a is an extremely potent proinflammatory mediator, as well as a potent chemotactic factor for neutrophils and other leukocytes. It causes histamine release, increases in vascular permeability, induces several cytokines production from leukocytes, enhances neutrophil-endothelial cell adhesion, and augments the humoral and cell-mediated immune response. C5a exerts actions by binding to G-protein-coupled receptor (C5aR/CD88) on the plasma membrane of target cells. Accordingly, the anaphylatoxin C5a is implicated in a variety of diseases such as rheumatoid arthritis, systemic lupus erythematosus, reperfusion injury, Alzheimer's disease, and sepsis.

References

1. Gerard, C. et al., 1994, Annu. Rev. Immunol. 12: 775-808.
2. Markus, S. et al., 2003, J. Immunol. 170: 6115-24.
3. Sumichika, H. et al., 2002, J. Biol. Chem. 277: 49403-7.
4. Riedemann, NC. et al., 2004, J. Immunol. 173: 1355-9.
5. Hsu, MH. et al., 1999, Blood. 10: 3241-9.
6. Monk, PN. et al., 2007, British Journal of Pharmacology. 152: 429-48.